US to Implement Steep Tariffs on Generic Medicine Imports Starting August 2028

New Delhi, India Jul 22, 2026 ALN: Washington: US President Donald Trump on Wednesday announced plans to onshore drug manufacturing by keeping tariffs on imported generic medicines at zero percent for two years before raising them to 100 percent in August 2028 and 200 percent thereafter — a move that could significantly impact India.

India is the largest exporter of generic drugs to the US, supplying a substantial portion of the pharmaceuticals consumed in the country. The proposed tariffs are part of a broader strategy aimed at reshoring manufacturing in the United States, a policy that has gained traction amidst growing concerns over supply chain vulnerabilities, especially highlighted during the COVID-19 pandemic.

In a post on Truth Social, Trump stated that beginning August 1, the US will maintain a zero percent tariff on all generic drugs brought into the country for two years, after which it will be raised to 100 percent for one year, and 200 percent thereafter. This timeline indicates a significant shift in US trade policy regarding pharmaceuticals, which could have far-reaching implications for both the US and Indian economies.

“Effective August 1st, 2026, all Generic Drugs being brought into the United States will continue to have a TARIFF of ZERO PERCENT for two years, after which the TARIFF will be raised to 100 percent for one year, and 200 percent thereafter,” Trump said. This policy aims to incentivize pharmaceutical companies to establish manufacturing facilities within the United States.

“This is done in order to RESHORE Generic Pharmaceutical Production into America, with a penalty to those Companies that decide not to build Plant and Equipment within the stated period of time given to them,” Trump added. The president emphasized that the objective of this policy is to protect the people of the United States, ensuring that the country has a reliable supply of essential medications.

India is often referred to as the “pharmacy of the world” as it supplies generic medicines to countries across the globe. The country has established itself as a crucial player in the global pharmaceutical market, particularly in the generic sector. In 2025, India exported USD 9.7 billion worth of pharmaceuticals to the US, accounting for 38 percent of its total global pharma exports of USD 25.8 billion, according to a Global Trade Research Initiative report. This substantial figure underscores the importance of Indian generic medicines in the US healthcare system.

Indian generic medicines are widely prescribed for conditions such as hypertension, diabetes, cancer, infectious diseases, and mental health. The availability of these drugs at lower prices has made them accessible to a larger segment of the US population. According to a report by the New York Times, generic drugs, including statins and antibiotics, account for approximately 90 percent of Americans’ prescriptions. They are predominantly manufactured in India, with a heavy reliance on China for active pharmaceutical ingredients (APIs). This reliance has raised concerns among lawmakers from both sides of the aisle, who have identified it as a national security vulnerability.

Critics of the proposed tariff increase, including doctors and supply chain experts, have expressed sharp concerns about the potential consequences of taxing imported generics. They argue that such measures threaten to raise costs, spur rationing, and lead to shortages of crucial drugs. The administration had previously indicated that generic drugs would be exempted from tariffs, making this policy shift particularly surprising to many stakeholders in the healthcare sector.

John Murphy III, chief executive of the Association for Accessible Medicines, a trade group for generic drug makers, stated on Tuesday evening that his industry will work with the administration and lawmakers “to pursue solutions that restore the generics industry to growth and to prioritize its place as a critical national security asset here in the US.” His comments reflect the growing concern within the industry regarding the implications of the proposed tariffs and the need for a collaborative approach to address these challenges.

The implications of these tariffs extend beyond just the pharmaceutical industry. The healthcare system in the US is heavily reliant on generic medications, which have been instrumental in controlling healthcare costs. A significant increase in tariffs could lead to higher prices for consumers, impacting their access to essential medications. This could disproportionately affect low-income patients who rely on affordable generic drugs for their treatment.

Furthermore, the proposed tariff structure could lead to a shift in the global pharmaceutical supply chain. If US companies are incentivized to manufacture drugs domestically, this may result in a decrease in imports from India and other countries. Such a shift could have economic repercussions for India, which has built a robust pharmaceutical industry that relies heavily on exports.

In addition to the economic implications, there are also potential public health concerns. A reduction in the availability of generic drugs could lead to increased healthcare costs and decreased access to necessary medications for millions of Americans. This situation raises questions about the sustainability of the US healthcare system and the potential for increased health disparities among different population groups.

As the implementation date for these tariffs approaches, stakeholders across the pharmaceutical industry, healthcare providers, and policymakers will need to engage in discussions to address the challenges posed by this policy shift. The balance between ensuring national security through domestic manufacturing and maintaining affordable access to essential medications will be a critical issue in the coming years.

In conclusion, the announcement of steep tariffs on imported generic medicines marks a significant shift in US trade policy that could have profound implications for the pharmaceutical industry, healthcare costs, and public health in the United States. As the country navigates this new landscape, the focus will need to be on finding solutions that protect both national interests and the health of its citizens.